Zusammenfassung
Die Begriffe Spondyloarthritis (SpA), Spondyloarthropathie oder Spondylarthropathie (heute wird bevorzugt der Terminus Spondyloarthritis verwendet) bezeichnen entzündlich-rheumatische Erkrankungen, die einige typische klinische, serologische und genetische Gemeinsamkeiten aufweisen. Charakteristisch ist eine Beteiligung des Achsenskeletts, der Sehnenansätze imSinne einer Enthesitis (z. B. ein Fersenschmerz) oder eine asymmetrischeOligoarthritis der unteren Extremitäten. Auch extraartikuläre Manifestationen wie eine Uveitis anterior sind häufig nachweisbar.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Amor B, Silva Santos R, Nahal R, Dougados M (1994) Predictive factors for the long term outcome of Spondyloarthropathies. J Rheumatol 21:1883–1887
Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439–R444
Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patientswith active ankylosing spondylitis. Rheumatology 44:342–348
Braun J, van den Berg R, Baraklios X et al (2011) 2010 Update of of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6): 896–904
Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193
Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320
Braun J, Landewe R, Hermann KG et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652
Braun J, Sieper J (2006) Spondyloarthritiden. Z Rheumatol 65:613–632
Blum U, Buitrago-Tellez C, Mundinger A et al (1996) Magnetic resonance imaging (MRI) for detection of active sacroiliitis — a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol 23:2107–2115
Brown MA, Wordsworth BP, Reveille JD (2006) Genetics of ankylosing spondylitis. Clin Exp Rheumatol 6 [Suppl 28] 20: S 43–49
Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankolysing spondylitis:Thedevelopment of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285
Calin A, Porta J, Fries JF, Schurmann DJ (1977) Clinical history as a screening test für ankylosing spondylitis. JAMA 237 (24): 2613–2614
Dagfinrud H, Kvien TK, Hagen KB (2008) Physiotherapie interventions forankylosing spondylitis. Cochrane Database Syst Rev 1: CD002822 18254008
Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227
Ebner W(2008) Therapieoptionen bei Morbus Bechterew. J Miner Stoffwechs 15:84–88
Ebner W (2008) Früherkennung des Morbus Bechterew in der allgemeinmedizinischen Praxis ÖGAM Newsletter 4
Bennett PH, Burch TA (1968) Population Studies of the Rheumatic Diseases. Exerpta Medica Foundation, Amsterdam. International Congress Series 148:305–313
Falkenbach A (Hrsg) (2005) Morbus Bechterew, Beratung, Betreuung, Behandlung. Springer, Wien New York
Garret S, Jenkinson T, Kennedy LG, et al (1994) A new approach to defining disease status in ankolysing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291
Haibel H, Rudwaleit M, Braun J, Sieper J (2002) Epidemiologie und Versorgung im Bereich der Spondyloarthropathien. Z Rheumatol 61:30–38
Langer H-E (2008) Biologicals in der frühen Behandlung des M. Bechterewund verwandter Spondyloarthritiden. Wien Med Wochenschr 158:200–205
Manger B (2005) Checkliste XXL Rheumatologie, 3._vollständig überarbeitete Auflage. Thieme, Stuttgart
Mau W, Zeidler H (2008). Spondylitis ankylosans. In: Zeidler H Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinischeRheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 907–923
Picozzi M, Weber M, Frey RA, Baumberger H (2002) Spondylitis ankylosans (M. Bechterew): Frühdiagnose und das bunte Bild der Krankheit. Schweiz Med Forum 2:232–237
Rainer F, Rudwaleit M (2005) Diagnosestellung. In: Falkenbach A (Hrsg) Morbus Bechterew, Beratung, Betreuung, Behandlung. Springer, Wien New York, pp 23–54
Rudwaleit M, Braun J, Sieper J (2009) ASAS-Klassifkationskriterien für axiale Spondyloarthritis. Z Rheumatol 68:591–593
Rudwaleit M, Feldtkeller E, Sieper J (2006). Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Ann Rheum Dis 65:1251–1252
Rudwaleit M, Landewé R, van der Heijde D et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68:770–776
Rudwaleit M, Listing J, Brandt J Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665–70
Rudwaleit M, Metter A, Listing J et al (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54:569–578
Rudwaleit M, Metter A, Listing J et al (2002) Clinical parameters in the differentiation of inflammatory back pain from non-inflammatory back pain. Ann Rheum Dis 61 [Suppl 1]:57
Rudwaleit M, Sieper J (2005) Frühdiagnose von Spondyloarthritiden mit besonderer Betonung auf die axialen Formen. Z Rheumatol 64:524–530
Rudwaleit M, Sieper J (2005) Diagnose und Frühdiagnose der Spondylitis ankylosans (Morbus Bechterew). Morbus Bechterew J 26:4–9
Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783
Sieper J, Braun J, Rudwaleit M et al (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61 [Suppl 3]:iii8–18
Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondylarthritis. Best Pract Res Clin Rheumatol 20:401–417
Sieper J, van der Heijde D, Landewé R et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: A real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68:784–788
Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Van der Heijde D, Sieper J, Maksymowych WP et al (2011) Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6): 905–908
Van der Linden S, Falkenbach A (2005) Prognose. In. Falkenbach A (Hrsg) Morbus Bechterew, Beratung, Betreuung, Behandlung. Springer, Wien New York, pp 71–81
Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452
Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of Infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52:1227–1236
Braun J, Sieper J (2006) Spondyloarthritiden. Z. Rheumatol 65:613–632
Cauza E, Dunky A (2006) Psoriasis Arthritis. Wien Med Wochenschr 156:587–595
Chandran V, Schentag CT, Gladman DD (2007) Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 57:1560–1563
Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of veterans affairs cooperative study. Arthritis Rheum 39:2013–2020
Feyertag J, Dunky A (2005) Arthritis psoriatica (Psoriasisarthritis). J Miner Stoffwechs 12:105–109
Finzel S, Englbrecht M (2011) Psoriasisarthritis. Z Rheumatol 70:775–789
Genth E (2008) Arthritis psoriatica und Arthritis bei gastrointestinalen Grundkrankheiten. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 547–553
Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: Epidemiology, clinical features, course and outcome. Ann Rheum Dis 64 [Suppl II]:ii14–ii17
Lynch M, Ng CT, Saber TP, Grier A et al (2008) The 28 Joint count underestimates extent of disease in Psoriatic arthritis. Arthritis Rheum 58 [Suppl]:363
Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390
Märker-Hermann E, Behrens F (2009) Psoriasisarthritis Zielkriterien der Behandlung. Z Rheumatol. 68:16–22
Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:51–78
Mumtaz A, Gallaher P, Kirby B et al (2011) development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70:272–277
Nell Duxneuner P, Stamm T, Aletaha D et al (2007) Measures associated with disease activity in psoriatic arthritis. Arthritis Rheum 56 [Suppl]:481
Österreichische Gesellschaft für Rheumatologie und Rehabilitation (2005) Österreichische Verschreibungsempfehlungen für TNF-Blocker bei Psoriasisarthritis. http://www. rheuma2000.at/
Ritchlin CT, Kavanaugh A, Gladman D et al (2008) Treatment recommendation for psoriatic arthritis. Arthritis Rheum 58 [Suppl]:363–364
Scheinecker C (2008) Pathogenese der Psoriasisarthritis. Fakten der Rheumatologie 2:7–8
Smolen J (2008) Therapie der Psoriasisarthritis. Fakten der Rheumatologie 2:17–18
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 54:2665–2673
Amor B (1983) Reiter’s syndrome and reactive arthritis. Clin Rheumatol 2(4):315–319
Bas S, Vischer TL (1998) Chlamydia trachomatis antibody detection and diagnosis of ractive arthritis. Br J Rheumatol 37:1054–1059
Calin A (1984) Reiter’s Syndrome. In: Calin A (ed) Spondyloarthropathies. Grune & Stratton, Orlando, FL, pp 844–849
Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:218–1227
El-Gabalawy HS, Goldbach-Mansky R, Smith D 2nd, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher HR Jr (1999) Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum 42:1696–1705
Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J (2001) Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis 60:337–343
Haibel H, Rudwaleit M, Sieper J, Zeidler H, Kuipers JG (2004) Diagnostik der reaktiven Arthritis. Z Rheumatol 63:211–215
Herzer P, Burmester GR, Genth E (2007) DiagnostischeKriterien Reaktive Arthritiden. In: Deutsche Gesellschaft für Rheumatologie e.V. Kommission für Qualitätssicherung (Hrsg) Qualitätssicherung in der Rheumatologie, 2._Auflage. Steinkopff
Kvien TK, Glennas A, Melby K, Granfors K, Andrup O, Karstensen B, Thoen JE (1994) Reactive arthritis: Incidence, triggering agents and clinical presentation. J Rheumatol 21:115–122
Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H (1991) Double-blind, placebocontrolled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34:6–14
Maki-Ikola O, Leirisalo-Repo M, Kantele A, Toivanen P, Granfors K (1991) Salmonellaspecific antibodies in reactive arthritis. J Infect Dis 164:1141–1148
Rabenau H, Berger A, Doerr HW, Weber B (1997) Testing for Chlamydia trachomatis in urine. Lancet 349:1024–1025
Schnarr S, Jendro M.C. Wollenhaupt J, Zeidler H (2008) Reaktive Arthritiden. In: Zeidler H, Zache J, Hiepe F (Hrgs) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 461–480
Sieper J, Braun J, Brandt J, Miksits K, Heesemann J, Laitko S, Sorensen H, Distler A, Kingsley G (1992) Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. J Rheumatol 19:1236–1242
Sieper J (2003) Reaktive Arthritis: Praktisches Vorgehen bei Diagnostik und Problematik der antibiotischenTherapie. Z Rheumatol 62:110–111
Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, Alten R, Keitel W, Groh A, Uksila J, Eggens U, Granfors K, Braun J (1999) No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebocontrolled study. Arthritis Rheum 42:1386–1396
Sieper J, Kingsley GH, Marker-Hermann E (1996) Aetiological agents and immunemechanisms in enterogenic reactive arthritis. Baillieres Clin Rheumatol 10:105–121
Sieper J, Rudwaleit M, Braun J, van der Heijde D (2002) Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum 46:319–327
Willkens RF (1981) Reiter’s syndrome. In: Arnett FC, Bitter T, Calin A, Fisher L, Ford DK, Good AE, Masi AT (eds) Evaluation of preliminary criteria for definite disease. Arthritis Rheum 24:844–849
Dallek R (2003) John F. Kennedy. Ein unvollendetes Leben. DVA, München
Dougados M, Van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of Spondylarthropathy. Arthritis Rheum 34:1218–1227
Genth E (2008) Arthritiden bei gastrointestinalen Erkrankungen. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 554–559
Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA (2007) Clin Gastroenterol Hepatol 5:1424–1429
Miehle W, Fehr K, Schattenkirchner M, Tillmann K (2000) Arthritis bei Zöliakie. In: Rheumatologie in Praxis und Klinik, 2._Auflage. Thieme, Stuttgart, p 709
Orchard TR, Wordsworth BP, Jwell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387–391
Puchner R (1999) EnteropathischeArthritiden. Arzt Praxis 53:676–681
Puchner R (2008) J. F. Kennedy. In: Loisl D, Puchner R (Hrsg) Diagnose Rheuma, 2._Auflage. Springer, Wien New York, p 136
Mau W, Zeidler H (2008) Sonstige entzündliche Spondylopathien. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 923–928
Mielants H, Veys EM, Cuvelier C et al (1995) The evolution of spondylarthropathies in relation to gut history: II. Histological aspects. J Rheumatol 22:2273–2278
Ronneberger M (2009) Enteropathische Arthritis. Z Rheumatol 68:329–336
Stein J (2004) Gastrointestinale Komplikationen. In: Falkenbach A (Hrsg) Morbus Bechterew, pp 211–245
Zochling J, Brandt J, Braun J (2005) The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology 44:1483–1491
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag/Wien
About this chapter
Cite this chapter
Puchner, R. (2012). Spondyloarthritiden. In: Rheumatologie aus der Praxis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1044-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1044-7_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1043-0
Online ISBN: 978-3-7091-1044-7
eBook Packages: Medicine (German Language)